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Abstract
Background: DNA damage checkpoints insure that the integrity of genomic DNA is faithfully maintained throughout the
eukaryotic cell cycle. In the presence of damaged DNA, checkpoints are triggered to delay cell cycle progression to allow for
DNA repair. In fission yeast, the kinases Chk1 and Cds1 are major components of these DNA damage checkpoint pathways.
Both Chk1 and Cds1 are important for viability in the presence of several DNA damaging agents. In this study we
hypothesized that Chk1 and Cds1 play a vital role in fission yeast cells ability to survive exposure to the DNA damaging
agent cisplatin. Cisplatin is a potent chemotherapeutic drug that interacts with DNA and causes both inter- and intra-strand
DNA cross-links.
Methodology/Principal Findings: Here, we demonstrated that treatment with cisplatin in fission yeast causes a Chk1-
dependent DNA damage signal. chk1
2 cells were sensitive to cisplatin and Chk1 was phosphorylated in response to
cisplatin treatment. We also showed that a Chk1-dependent DNA damage checkpoint pathway is activated in a dose-
dependent fashion in cells challenged with cisplatin. Furthermore the Cds1 checkpoint kinase was also important for
viability in cisplatin challenged cells. In cds1
2 cells, cisplatin treatment reduced cell viability and this phenotype was
exacerbated in a chk1
2/cds1
2 background.
Conclusions/Significance: Thus, we conclude that the concerted effort of both major checkpoint kinases in fission yeast,
Chk1 and Cds1, protect cells from cisplatin induced DNA damage. These observations are significant because they suggest
that various classes of inter-strand crosslinking agents may generate slightly different lesions as work by others did not
observe loss of viability in cds1
2 cells treated with other crosslinking agents like nitrogen mustard.
Citation: Paparatto D, Fletcher D, Piwowar K, Baldino K, Morel C, et al. (2009) The Schizosaccharomyces pombe Checkpoint Kinases Chk1 and Cds1 Are Important
for Cell Survival in Response to Cisplatin. PLoS ONE 4(7): e6181. doi:10.1371/journal.pone.0006181
Editor: Daniel Lew, Duke University Medical Centre, United States of America
Received April 27, 2009; Accepted June 11, 2009; Published July 9, 2009
Copyright:  2009 Paparatto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was generously supported by the Merck/AAAS Undergraduate Science Research Program grant to S.D.. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sdunaway@drew.edu
Introduction
Cell cycle checkpoints are signal transduction pathways that
control the stepwise progression of cell division and arrest the cell
cycle in the presence of damaged DNA, replication stresses or
spindle disruption. As cells divide, their genome is under constant
threat by intrinsic damage and exogenous agents that cause DNA
lesions. Failure to repair these lesions can lead to mutation of the
DNA, resulting in genomic instability, and cancer in higher
eukaryotes. The DNA damage checkpoint specifically delays entry
into mitosis in the presence of damaged DNA to provide cells
enough time to repair damaged DNA before permanent mutations
are made [1]. Many of the proteins involved in the checkpoint
pathway have been identified genetically in budding and fission
yeasts and are well conserved throughout eukaryotic evolution.
Mutation or deletion of these proteins leads to a failure of cells to
arrest cell cycle progression in the presence of DNA damage and
manifests itself as a profound loss of cell viability [2–8].
In fission yeast, a major DNA damage induced cell cycle
checkpoint occurs at the G2/M border and the protein kinase
Chk1 is an essential component of this response. Deletion of chk1
+
results in both sensitivity to DNA damaging agents and checkpoint
defects, such as a failure to restrain cell cycle in the presence of
damaged DNA [4,9,10]. Chk1 homologs have been found in all
organisms studied [11]. Chk1 kinase activity is activated by DNA
damage and is dependent on several upstream ‘‘rad’’ components
of the checkpoint signaling pathway (Rad1, Rad9, Hus1, Rad26,
Rad3 and Crb2) [3,6,10,12–15]. Overexpression of Chk1 can
partially rescue the UV sensitivity of other ‘rad’ checkpoint
mutants further implicating it as a downstream component of the
checkpoint pathway [4].
In response to many types of DNA damage, Chk1 is
phosphorylated on amino acid S345 and this event leads to the
activation of the kinase activity of Chk1, which triggers a G2/M
checkpoint arrest [9,10,12]. The DNA damaged induced phos-
phorylation of S345 on Chk1 is dependent on Rad3 in fission
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Chk1 is controlled by the Rad3 ortholog ATR (ATM and Rad3
related) and has been shown to occur directly in response to DNA
damage [16–18]. Disruption or mutation of any of the ATM
family members in mammals (ATM or ATR) or fission yeast
(Rad3) leads to severe defects in DNA damage checkpoint
signaling [3,19–21].
Although fission yeast Chk1 is phosphorylated and activated by
multiple types of DNA damaging agents, Chk1 is only weakly
activated during replication stress induced after treatment with the
replication inhibiting drug hydroxyurea [12]. This observation
distinguishes Chk1 from the another major effector kinase of the
cell cycle checkpoint apparatus, Cds1 [22]. Cds1 (Checking DNA
Synthesis) was originally identified as a suppressor of a mutant
allele of DNA polymerase a and is thought to oversee the cell cycle
checkpoint in response to replication stress [23]. Cds1 is
homologous to Rad53 in budding yeast and Chk2 in mammals
[24–26]. Deletion of cds1
+ results in sensitivity to DNA damaging
agents and replication inhibitors [22]. Additionally, Cds1 kinase
activity is stimulated by exposure to UV light and is required to
delay S phase progression after UV irradiation and hydroxyurea
treatment [22,27]. These observations implicate Cds1 in both the
DNA damage and replication checkpoints operating during S
phase. Activation of Cds1 requires the upstream ‘rad’ checkpoint
proteins but not Chk1 [22]. Chk1 is not activated in the presence
of the replication checkpoint inducing drug hyrdoxyurea;
however, in a cds1D background Chk1 becomes strongly
phosphorylated in response to hydroxyurea treatment [22]. This
observation suggests there is some functional overlap between the
two checkpoint effector kinases. Moreover, cells deficient in either
Cds1 or Chk1 are somewhat sensitive to DNA damage, however, a
cds1D/chk1D double delete is as profoundly sensitive as a deletion
of the ‘‘upstream’’ components of the checkpoint pathway, like
Rad3 [22,28,29].
The DNA damage checkpoint works by controlling the Y15
phosphorylation of the cyclin-dependent kinase Cdc2 [30]. Chk1
is thought to control the G2/M checkpoint response by indirectly
regulating Cdc2, the main controller of G2/M transition in fission
yeast. Specifically, Chk1 phosphorylates Wee1 and Cdc25, both
regulators of Cdc2, in response to DNA damage to promote
checkpoint arrest [31–33]. These observations suggest there is a
direct link between DNA damage detection and cell cycle control
pathways [32–35].
The focus of this study was to investigate the sensitivity of fission
yeast cells lacking Chk1, Cds1 or both to the DNA crosslinking
drug cisplatin, a chemotherapeutic drug that generates both inter-
and intra-strand DNA crosslinks [36]. Previous studies in fission
yeast have examined the roles Chk1 and Cds1 play in maintaining
viability in response to other inter-strand crosslinking agents (ICL)
like nitrogen mustard and mitomycin C (MMC) [37,38]. The
direct involvement of human Chk1 and Chk2 have also been
investigated in response to cisplatin and although these proteins
are highly conserved, functional differences do exist [18,39].
Therefore, the more information gained from the study of Chk1
and Cds1 in fission yeast could provide further insight into the
functions of the mammalian homologs. Here we demonstrate that
fission yeast Chk1 is important for cell survival in response to
cisplatin treatment. Furthermore, we show that Chk1 is phos-
phorylated and a Chk1-dependent DNA damage checkpoint
response is triggered by cisplatin. We also show that cds1D cells
display a moderate sensitivity to cisplatin that is exacerbated in a
cds1D/chk1D double delete. Our results suggest that in response to
cisplatin, both the Chk1 and Cds1 pathways function together to
maintain cell viability.
Results
chk1D strains are sensitive to cisplatin
To further investigate the response of the fission yeast
Schizosaccharomyces pombe to ICL agents, we determined the
sensitivity of a strain lacking the DNA damage checkpoint kinase,
Chk1, to cisplatin (Fig. 1a,c). Cells were grown to mid-log phase,
treated with 200 mM cisplatin and 10 fold serial dilutions plated on
YEA plates (Fig. 1a). When compared to wildtype cells, chk1D cells
were sensitive to cisplatin and this sensitivity was intermediate
when compared to rad3D cells (Fig. 1a). To ensure that these effects
were due to the loss of chk1
+, and not due to the acquisition of a
suppressor we re-introduced the chk1
+ gene on a high copy
plasmid. When transformed into the chk1
2 strain, the plasmid-
borne copy of the chk1
+ gene was able to rescue the cisplatin
sensitivity, whereas, the strain transformed with an empty plasmid
remained sensitive to cisplatin treatment (Fig. 1b).
To confirm the observation made in Figure 1a that chk1D cells
were sensitive to cisplatin, colony counting assays were performed
in which cells were grown to mid-log phase, treated with either
100 mM or 200 mM cisplatin and 750 cells were plated on YEA.
These plates were then incubated for 3 days at 30uC and scored
for colony survival (Fig. 1c). chk1D cells displayed 62% survival
when challenged with 100 mM cisplatin compared to 86% survival
of a wildtype strain (Fig. 1c). As a control rad3D cells displayed less
than 1% survival after 100 mM cisplatin treatment (Fig. 1c). At
200 mM cisplatin concentration viability decreased to 17% for
chk1D cells and 64% for wildtype cells (Fig. 1c). Again, rad3D cells
served as a control and displayed less than 1% survival after
200 mM cisplatin treatment (Fig. 1c). The results from these
experiments revealed that chk1D cells display a dose-dependent
sensitivity to cisplatin compared to wild type cells and this
sensitivity was not as severe as the extreme sensitivity observed in
rad3D cells (Fig. 1c).
Together, these results indicate that chk1
+ is important for the
viability of fission yeast strains challenged with the DNA
crosslinking agent cisplatin.
Chk1 is phosphorylated and activates a DNA damage
checkpoint arrest in response to cisplatin treatment
Given the observations that chk1D strains are sensitive to
treatment with the DNA crosslinking agent cisplatin we investi-
gated whether Chk1 was activated in cells treated with cisplatin.
To address this issue, we performed western blot analysis on a
fission yeast strain that expressed a functional hemmaglutinin
tagged (HA) allele of chk1
+ (chk1:HA) in the presence or absence of
cisplatin (Fig. 2a,b). The chk1:HA expressing strain and a chk1D
strain were grown to mid-log phase and the indicated strains were
treated with 200 mM cisplatin for one hour and subject to SDS-
PAGE and western blot analysis with an antibody directed against
the HA epitope tag. Whereas, the protein lysate from the
untreated strain only contained a single species of Chk1 protein,
the lysate from the cisplatin treated cells contained a second slower
migrating form of Chk1 (Fig. 2a). It has previously been reported
that Chk1 protein becomes phosphorylated in response to
exposure to a variety of different DNA damaging agents like UV
light and camptothecin, and this phosphorylation event results in
the gel mobility shift of Chk1 [12,40]. To confirm the identity of
the bands observed in the western blots as Chk1, a chk1D strain
was used as a negative control (Fig. 2a,b).
Next, we investigated whether the phosphorylation of Chk1
induced by cisplatin was dependent upon the upstream compo-
nents of the DNA damage checkpoint response pathway. To
accomplish this, we performed western blot analysis on protein
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chk1
+ but lacking either rad1
+ or rad3
+ (chk1:HA, chk1:HArad3D,
chk1:HArad1-1). Rad1 is a component of the Rad1, Rad9, Hus1 (9-
1-1) complex of proteins which loads onto to chromatin and plays
a role in phosphorylating Chk1 in response to DNA damage (as
reviewed by [41]). Both rad1
+ and rad3
+ function upstream of chk1
+
in the checkpoint response pathway. When these strains were
treated with cisplatin only the wild type strain expressing
Chk1:HA contained phosphorylated Chk1. Chk1:HA in the
rad1-1 and the rad3D strains failed to phosphorylate Chk1
(Fig. 2b). Taken together we conclude that Chk1 becomes
phosphorylated in response to cisplatin treatment and that this
event is dependent on the upstream components of the DNA
damage checkpoint response pathway in fission yeast.
We also investigated whether cisplatin activated a Chk1-
dependent DNA damage checkpoint response. We used strains
Figure 1. Deletion of chk1
+ results in cisplatin sensitivity. A. The wildtype, chk1D, and rad3D cells were grown to mid-log phase in YEA media,
treated with 200 mM cisplatin for 1 hour, resuspended to 1610
8cells/ml and serially diluted and spotted on YEA plates. Plates were photographed
after three days of growth at 30uC. B. The wildtype and chk1D cells transformed with an either empty pSP1 or pSP1-chk1
+ were grown to mid-log
phase in SC-leu media, treated with 200 mM cisplatin for 1 hour, resuspended to 1610
7cells/ml and serially diluted and spotted on SC-leu plates.
Plates were photographed after four days of growth at 30uC. C. The wildtype, chk1D, and rad3D cells were grown to mid-log phase in YEA media,
treated with either 100 mM or 200 mM cisplatin for 1 hour and cells plated in triplicate on YEA and incubated for 3 days. Mean survival was calculated
as a percentage of colonies appearing on untreated plates. Data represented here is typical of one of 3 independent experiments. Error bars
represent standard deviation of the mean.
doi:10.1371/journal.pone.0006181.g001
Cisplatin Survival in S.pombe
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6181harboring the temperature sensitive allele cdc25-22 either contain-
ing or lacking chk1
+. At the restrictive temperature of 36.5uC cells
expressing this allele arrest in G2, prior to mitosis, with an
elongated phenotype. When returned to the permissive temper-
ature of 25uC the cells can enter mitosis. These cells were arrested
at G2 by shifting the culture to the restrictive temperature 36.5uC,
treated with cisplatin, and released at the permissive temperature
25uC. Bi-nucleated cells were scored as an indication of cells that
had entered or completed mitosis. Cells containing chk1
+ were able
to delay mitotic entry in a dose-dependent fashion when
challenged with cisplatin, whereas, chk1D cells were unable to do
so and proceeded into mitosis (Fig. 2c). This premature entry into
mitosis observed in the chk1D cells most likely results in the
inability to faithfully repair cisplatin-induced DNA damage
resulting in the loss of viability as observed in Figure 1a,b. Taken
together this data supports the hypothesis that Chk1 is important
for cell viability in the presence of cisplatin and that this cell
viability is maintained by Chk1’s ability to trigger a DNA damage
checkpoint response in response to the cisplatin treatment.
Furthermore, the duration of the cell cycle delay is dose dependent
consistent with the notion that the delay allows time for repair of
the cisplatin-induced damage.
Figure 2. Cisplatin causes Chk1 to become phosporylated and activates a Chk1-dependent DNA damage checkpoint. A and B.
Cultures from chk1D, chk1-HA, rad3Dchk1-HA, and rad1-1chk1-HA were grown to mid-log phase in YEA media at 30uC and treated with 200 mM
cisplatin for one hour then harvested and analysed by western blot analysis with an antibody directed against the HA epitope tag at the C- terminus
of Chk1. C. The chk1cdc25-22 and chk1Dcdc25-22 strains were grown to mid-log phase at 25uC and shifted to 36.5uC for 3 hours to synchronize cells
in G2 phase of the cell cycle. This was followed by treatment with either 100 mM or 200 mM cisplatin for one hour at 36.5uC and then the strains were
released to 25uC to permit cycling. The percentage of binulceate cells was scored over a 4 hour time period as an indication of cells progressing into
and thru mitosis.
doi:10.1371/journal.pone.0006181.g002
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response to cisplatin
Although Chk1 mediates a major G2 checkpoint that delays
mitosis, additional checkpoint pathways exist that delay entry into
or progression through S phase. One of these pathways operates
during the DNA synthesis phase of the cell cycle and this
checkpoint is mediated by the Rad3-Cds1 pathway [11,27]. We
investigated whether Cds1 also played a role in maintaining cell
viability in response to cisplatin as reports suggest that Chk1 and
Cds1 may functionally overlap to protect cells against certain types
of DNA damage [22]. We performed serial dilution spotting of
cells that were treated with 200 mM cisplatin (Fig. 3a). cds1D cells
were only slightly sensitive to cisplatin as compared to WT cells,
whereas chk1D and rad3D cells displayed greater sensitivity.
Strikingly, chk1D/cds1D double delete cells displayed an additive
sensitivity to cisplatin treatment comparable to rad3D cells (Fig. 3a).
This observation was confirmed by colony counting experiments
where cds1D and chk1D cells displayed 47% and 14% survival
when treated with 200 mM cisplatin. Whereas, the chk1D/cds1D
delete cells displayed only 1% survival, similar to that observed in
rad3D cells (Fig. 3b). We also observed a mild sensitivity of cds1D
cells to nitrogen mustard in our colony counting assay (data not
Figure 3. Both Chk1 and Cds1 are required to maintain cell viability in the presence of cisplatin induced damage. A. The wildtype,
chk1D, cds1D, chk1Dcds1D and rad3D cells were grown to mid-log phase in YEA media, treated with 200 mM cisplatin for 1 hour, resuspended to
1610
7cells/ml and serially diluted and spotted on YEA plates. Plates were photographed after three days of growth at 30uC. B. The wildtype, chk1D,
cds1D, chk1DcdsD, and rad3D cells were grown to mid-log phase in YEA media, treated with or 200 mM cisplatin for 1 hour and cells plated in
triplicate on YEA and incubated for 3 days. Mean survival was calculated as a percentage of colonies appearing on untreated plates. Data represented
here is typical of one of 2 independent experiments. Error bars represent standard deviation of the mean.
doi:10.1371/journal.pone.0006181.g003
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checkpoint kinases appear to play a role in protecting cells from
cisplatin and additively they cooperate to resolve both inter-and
intra-strand crosslinking.
Discussion
The results of our studies demonstrate that the DNA damage
checkpoint effector kinase Chk1 plays a vital role in maintaining
fission yeast cell viability in the presence of cisplatin induced DNA
damage. Cells lacking Chk1 lose viability following cisplatin
treatment (Fig. 1a,c). The cisplatin survival defect demonstrated
here can be rescued by re-introduction of chk1
+ on a high copy
plasmid further implicating Chk1 (Fig. 1b). This observation
agrees with the importance of Chk1 in response to the inter-strand
cross-linking agents nitrogen mustard and MMC [37]. The fission
yeast Chk1 protein is also activated after cisplatin treatment as
evidenced by the appearance of a phosphorylated form of Chk1
(Fig. 2a,b). These observations are consistent with those reported
for human Chk1 as Zhao and Piwinica-Worms demonstrated that
human Chk1 was phosporylated in response to cisplatin treatment
[18]. Furthermore, this DNA damage mediated activation of Chk1
is dependent on the upstream ‘rad’ components of the DNA
damage checkpoint response pathway as has been reported for
other DNA damaging agents like UV, c, and camptothecin
(Fig. 2b) [12,40].
Additionally, we demonstrated in this study that cisplatin
triggered a Chk1-dependent DNA damage checkpoint arrest
(Fig. 2c). The duration of the delay is extended with higher doses
of cisplatin indicating that the DNA damage generated by cisplatin
does indeed trigger a G2/M checkpoint response in Schizosacchar-
omyces pombe as has been demonstrated to occur in response to
other crosslinking drugs like nitrogen mustards and MMC and in
the budding yeast in response to cisplatin [37,42]. In this study, we
also investigated whether the replication checkpoint effector kinase
Cds1 was involved in maintaining cell viability in response to
cisplatin damage as has been reported for other DNA damaging
agents, such as, UV, HU, and c irradiation [22]. Specifically, our
sensitivity data show that cds1D cells displayed a mild sensitivity as
compared to wildtype cells and that cds1D/chk1D cells displayed an
‘additive’ loss of viability comparable to that observed in rad3D
cells upon cisplatin treatment (Fig. 3a,b). The ‘additive’ phenotype
observed in the cds1D/chk1D cells is in complete agreement with
similar observations observed in the cds1D/chk1D double delete
cells in response to UV and c irradiation [22]. It has previously
been reported in fission yeast that cds1D cells were not sensitive to
other types of crosslinking agents, like nitrogen mustard, and in
fact displayed a slight resistance to those drugs. However, cds1D/
chk1D double delete cells displayed slightly more sensitivity than
chk1D cells in those studies, consistent with our cisplatin results
[37]. The difference in sensitivity of cds1D cells between these two
studies with regards to cisplatin and other crosslinking drugs like
nitrogen mustard is most likely explained by a difference in
experimental procedure. When we performed our colony counting
assay with nitrogen mustard we observed sensitivity in the Cds1
deficient strain similar to that observed in our cisplatin treated cells
(data not shown). In the studies performed by Lambert et al, they
observed that Cds1 kinase activity was upregulated in response to
nitrogen mustard treatment to the same level observed with the
common replication checkpoint inducing agent, HU [37]. This
result suggested that Cds1 plays some role in how cells respond to
crosslinked DNA which is consistent with our results. Additional
evidence implicating Cds1 in this response pathway comes from
studies of Cds1 orthologs in both budding yeast (Rad53) and
mammalian cells (Chk2). Rad53D budding yeast are sensitive to
cisplatin and in multiple mammalian cell types Chk2 is
phosphorylated and activated in response to cisplatin treatment
[39,42]. A Chk2-dependent checkpoint arrest has recently been
shown to be triggered by the nitrogen mustard class bi-functional
alkylating agent bendamustine [43].
Together our data supports the notion that the replication and
DNA damage checkpoint responses in fission yeast work together
to handle potential threats to genomic stability. Currently,
mammalian Chk1 and Chk2 are chemotherapeutic targets for
kinase inhibitor drugs like UCN-01 aimed at disrupting these
checkpoint responses in response to DNA damage [44]. The goal
of these approaches by others remains to develop clinically
successful combinatorial chemotherapies using drugs like UCN-01
and cisplatin in attempt to increase tumor cell killing, while at the
same time reducing the requirement for high doses of chemother-
apeutic drugs, like cisplatin that are known to be highly toxic to
patients. Fission yeast has proven an extremely powerful tool in
elucidating the DNA damage checkpoint pathways that have
clinical relevance. We are currently attempting to develop cisplatin
analogs to look at whether modifications of the lead compound
alter the checkpoint response with the hope of further defining the
cellular response pathway. The data from those studies could
prove useful in the further design of kinase inhibiting drugs aimed
at eliminating Chk1 or Cds1/Chk2 activity.
Materials and Methods
Yeast strains, media, and growth conditions
Yeast strains used in this study are listed in Table 1. Strains were
grown in SC medium with appropriate amino acid supplements at
75 mg/ml or in rich yeast extract (YE) medium supplemented with
adenine. Standard recipes were used for YE [45]. Strains were
grown at 30uC unless otherwise indicated.
Yeast transformation
Strains were grown in YEA media to a density between 5610
6–
1610
7 cells/ml. The cells were pelleted and washed with 20 mls of
sterile water. Cells were then pelleted and washed with 20 mls
0.1 M lithium acetate, pH 4.9. The cells were pelleted and
Table 1. Yeast Strains Used in This Study.
Strain Genotype
972 h
2 (wild type)
NW158 h
+ chk1::ura4 ura4-D18 leu1-32 ade6-216
NW240 h
2 rad3::LEU2 leu1-32 ura4-D18 his3
KB1 h
2 leu1-32/pSP1 (empty plasmid)
KB2 h
2 leu1-32/pSP1-chk1:ep
KB3 h
+ chk1::ura4 ura4-D18 leu1-32 ade6/pSP1 (empty plasmid)
KB4 h
+ chk1::ura4 ura4-D18 leu1-32 ade6/pSP1-ck1:ep
NW223 h
+ chk1:ep ade6-216 leu1-32
NW238 h
+ chk1:ep ade6-216 leu1-32 rad1-1
NW246 h
2 chk1:ep ade6-216 leu1-32 rad3::LEU2
NW404 h
+ cdc25-22 chk1::ura4 ura4-D18 leu1-32 ade6-210
SP532 h
+ cdc25-22 ade6-210 leu1-32
NW268 h
2 cds1::ura4 ura4-D18 leu1-32
NW371 h
+ chk1::ura4 cds1::ura4 ura4-D18 leu1-32 ade6-216
doi:10.1371/journal.pone.0006181.t001
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1610
9 cells/ml and incubated at 30uC without shaking for 30
minutes. 100 ml of cells were then aliquoted to a tube containing
2–5 mg of plasmid DNA (pSP1-Chk1:HA), mixed gently and
incubated at 30uC for 30 minutes. 290 ml of 50% polyethylene
glycol-3350 was added, cells were gently mixed and incubated at
30uC for 30 minutes. Samples were then heat shocked at 42uC for
15 minutes. Cells were then pelleted and resuspended in 100 mlo f
SC-leu media and plated on proper selection plates.
Cisplatin Survival Assay
Cisplatin (cis-diamineplatinumII dichloride) was obtained from
Sigma (P-4394) and prepared in YEA media. Cells were grown to
mid-log phase and treated with 100–200 mM cisplatin containing
YEA media for one hour and then plated for 10-fold serial dilution
spotting, individual colony counting, or used to assay DNA
damage checkpoint activation as described [9].
DNA damage checkpoint assay
To assay for the activation of the Chk1-dependent DNA
damage checkpoint, a cdc25-22 block release experiment was
performed as previously described with minor modifications [46].
The cdc25-22 strains used here were arrested at the restrictive
temperature of 36.5uC for three hours followed by a one hour
treatment with the indicated doses of cisplatin (Sigma P-4394) at
36.5uC.
Lysate preparation and immunoblotting
Cells were harvested by centrifugation and lysed in phosphate
buffered saline (PBS) containing Complete Protease Inhibitor
(Roche Diagnostics) using glass beads and a FastPrep (Bio101) cell
disruptor. Supernatant was collected from the lysed cells by
centrifugation at 3000 rpm for 5 minutes. Aliquots were separated
on Biorad 7.5% SDS-PAGE gels (161-1100), transferred to Biorad
Immun-Blot PVDF membrane (162-0218), and probed with
12CA5 antibody to detect the HA epitope at the c-terminus of
Chk1. Blocking of the membranes and all antibody incubations
and washes were performed in 1% milk and 0.05% Tween-20 in
PBS. 12CA5 antibody was used at 1:500 and a peroxidase coupled
secondary antibody (Santa Cruz-sc-2005) was used at 1:1000. The
SuperSignal West Dura Extended Duration Substrate (Thermo
Scientific-34075) was used for detection. Membranes were then
detected in an Alpha Innotech FluorChem SP imaging system.
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